RU2009121626A - Glucagon-like protein-1 receptor agonists (GLP-1R) - Google Patents
Glucagon-like protein-1 receptor agonists (GLP-1R) Download PDFInfo
- Publication number
- RU2009121626A RU2009121626A RU2009121626/10A RU2009121626A RU2009121626A RU 2009121626 A RU2009121626 A RU 2009121626A RU 2009121626/10 A RU2009121626/10 A RU 2009121626/10A RU 2009121626 A RU2009121626 A RU 2009121626A RU 2009121626 A RU2009121626 A RU 2009121626A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- antibody
- replaced
- compound
- connecting residue
- Prior art date
Links
Abstract
1. Соединение, содержащее пептид с последовательностью: ! R1-H1Aib2E3G4T5F6T7S8D9L10S11K12Q13M14E15E16E17A18V19R20L21F22I23E24W25L26K27N28G29G30P31S32S33G34A35P36P37P38S39-X40-R2, ! где R1 отсутствует или представляет собой СН3, С(O)СН3, С(O)CH2CH3, С(O)СН2СН2СН3 или С(O)СН(CH3)СН3; и R2 отсутствует или представляет собой ОН, NH2, NH(CH3), NHCH2CH3, NHCH2CH2CH3, NHCH(СН3)СН3, NHCH2CH2CH2CH3, NHCH(СН3)СН2СН3, NHC6H5, NHCH2CH2OCH3, NHOCH3, NHOCH2CH3, защитную группу для карбокси, жирнокислотную группу липидов или углевод; ! и X40 представляет собой соединяющий остаток или отсутствует; и где один из L10, S11, K12, Q13, M14, E16, E17, V19, R20, L21, E24, L26, K27, N28, S32, S33, G34, А35, Р36, Р37, Р38, S39 или X40 заменен на соединяющий остаток (-[LR]-), содержащий нуклеофильную боковую цепь, ковалентно присоединяемую к линкеру L, способному к ковалентному связыванию с антигенсвязывающим сайтом антитела, и где структура соединяющего остатка, когда он присоединен клинкеру, имеет формулу: ! , ! где u равно 1, 2 или 3; v равно 1 или 2; t равно 1, 2 или 3; r равно 1 или 2; s равно 0; и q равно 1 или 2. ! 2. Соединение по п.1, где u равно 2, v равно 2, t равно 2, r равно 2, и q равно 2. ! 3. Соединение по п.1, где R1 представляет собой С(O)СН3. ! 4. Соединение по п.1, где R2 представляет собой NH2. ! 5. Соединение по п.1, где один из S11, K12, Q13, М14, Е16, Е17, V19, R20, L21, Е24, L26, K27, N28, S32, G34, Р36, Р38 или X40 заменен на указанный соединяющий остаток. ! 6. Соединение по п.1, где один из S11, K12, Q13, М14, Е16, Е17, V19, R20, L21, Е24, K27, N28, S32, G34, Р36, Р38 или X40 заменен на указанный соединяющий остаток. ! 7. Соединение по п.1, где один из S11, K12, Q13, М14, Е16, Е17, V19, R20, L21, Е24, K27, N28, Р38 или X40 заменен на указанный соединяющий остаток. ! 8. Соединение по п.1, где один из K12, М14, V19, R20, L21 и Е24 заменен на указанный соединяющий остаток. ! 9. Соединение по п.1, где один из М14, V19, R20 и L21 заменен на указанный соединяющий остаток 1. The compound containing the peptide with the sequence:! R1-H1Aib2E3G4T5F6T7S8D9L10S11K12Q13M14E15E16E17A18V19R20L21F22I23E24W25L26K27N28G29G30P31S32S33G34A35P36P37P38S39-X40-R2,! where R1 is absent or represents CH3, C (O) CH3, C (O) CH2CH3, C (O) CH2CH2CH3 or C (O) CH (CH3) CH3; and R2 is absent or represents OH, NH2, NH (CH3), NHCH2CH3, NHCH2CH2CH3, NHCH (CH3) CH3, NHCH2CH2CH2CH3, NHCH (CH3) CH2CH3, NHC6H5, NHCH2CH2OCH3, NHOCH3, NHOCH2CH3, a carboxylic acid protecting group carbohydrate; ! and X40 represents a connecting residue or is absent; and where one of L10, S11, K12, Q13, M14, E16, E17, V19, R20, L21, E24, L26, K27, N28, S32, S33, G34, A35, P36, P37, P38, S39 or X40 is replaced to the connecting residue (- [LR] -) containing a nucleophilic side chain covalently attached to the linker L, capable of covalent binding to the antigen-binding site of the antibody, and where the structure of the connecting residue, when attached to the clinker, has the formula:! ! where u is 1, 2 or 3; v is 1 or 2; t is 1, 2 or 3; r is 1 or 2; s is 0; and q is 1 or 2.! 2. The compound according to claim 1, where u is 2, v is 2, t is 2, r is 2, and q is 2.! 3. The compound according to claim 1, where R1 represents C (O) CH3. ! 4. The compound according to claim 1, where R2 is NH2. ! 5. The compound according to claim 1, where one of S11, K12, Q13, M14, E16, E17, V19, R20, L21, E24, L26, K27, N28, S32, G34, P36, P38 or X40 is replaced by the specified connecting the remainder. ! 6. The compound according to claim 1, where one of S11, K12, Q13, M14, E16, E17, V19, R20, L21, E24, K27, N28, S32, G34, P36, P38 or X40 is replaced by the specified connecting residue. ! 7. The compound according to claim 1, where one of S11, K12, Q13, M14, E16, E17, V19, R20, L21, E24, K27, N28, P38 or X40 is replaced by the specified connecting residue. ! 8. The compound according to claim 1, where one of K12, M14, V19, R20, L21 and E24 is replaced by the specified connecting residue. ! 9. The compound according to claim 1, where one of M14, V19, R20 and L21 is replaced by the specified connecting residue
Claims (25)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87904807P | 2007-01-05 | 2007-01-05 | |
US60/879,048 | 2007-01-05 | ||
US93983107P | 2007-05-23 | 2007-05-23 | |
US60/939,831 | 2007-05-23 | ||
US60/945,319 | 2007-06-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011127520/10A Division RU2011127520A (en) | 2007-01-05 | 2011-07-06 | Glucagon-like protein-1 receptor agonists (GLP-1R) |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009121626A true RU2009121626A (en) | 2011-02-10 |
RU2432361C2 RU2432361C2 (en) | 2011-10-27 |
Family
ID=44998240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009121626/10A RU2432361C2 (en) | 2007-01-05 | 2008-01-07 | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2432361C2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015155141A1 (en) * | 2014-04-07 | 2015-10-15 | Sanofi | Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4 |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104371019B (en) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | It is a kind of can with GLP-1R specifically bind antibody and its with the fused protein of GLP-1 |
-
2008
- 2008-01-07 RU RU2009121626/10A patent/RU2432361C2/en not_active IP Right Cessation
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10758592B2 (en) | 2012-10-09 | 2020-09-01 | Sanofi | Exendin-4 derivatives as dual GLP1/glucagon agonists |
US10253079B2 (en) | 2012-12-21 | 2019-04-09 | Sanofi | Functionalized Exendin-4 derivatives |
US9670261B2 (en) | 2012-12-21 | 2017-06-06 | Sanofi | Functionalized exendin-4 derivatives |
US9745360B2 (en) | 2012-12-21 | 2017-08-29 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists |
US9789165B2 (en) | 2013-12-13 | 2017-10-17 | Sanofi | Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
US9750788B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Non-acylated exendin-4 peptide analogues |
US9751926B2 (en) | 2013-12-13 | 2017-09-05 | Sanofi | Dual GLP-1/GIP receptor agonists |
US9694053B2 (en) | 2013-12-13 | 2017-07-04 | Sanofi | Dual GLP-1/glucagon receptor agonists |
US9758561B2 (en) | 2014-04-07 | 2017-09-12 | Sanofi | Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9771406B2 (en) | 2014-04-07 | 2017-09-26 | Sanofi | Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
US9775904B2 (en) | 2014-04-07 | 2017-10-03 | Sanofi | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
WO2015155141A1 (en) * | 2014-04-07 | 2015-10-15 | Sanofi | Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10806797B2 (en) | 2015-06-05 | 2020-10-20 | Sanofi | Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
US9982029B2 (en) | 2015-07-10 | 2018-05-29 | Sanofi | Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
RU2432361C2 (en) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009121626A (en) | Glucagon-like protein-1 receptor agonists (GLP-1R) | |
JP6952835B2 (en) | Antibody-drug conjugate | |
JP7103953B2 (en) | Antibody drug conjugate with a derivative of amatoxin as a drug | |
KR101988005B1 (en) | Amatoxin-conjugates with improved linkages | |
JP5559439B2 (en) | Branched linkers for protein drug conjugates | |
AU2013336409B2 (en) | Drug-protein conjugates | |
JP2020525542A5 (en) | ||
RU2012106200A (en) | GLUCAGON-LIKE PEPTIDE-1 (GLP-1R) RECEPTOR AGONISTS FOR TREATMENT OF AUTOIMMUNE DISORDERS | |
RU2755728C2 (en) | New amanitin conjugate | |
JP7335957B2 (en) | Antibody-ALK5 inhibitor conjugates and uses thereof | |
JP2010509315A5 (en) | ||
CN107530442A (en) | Site-specific antibodie drug conjugate | |
KR20230008723A (en) | charge variant linker | |
JP2020524675A (en) | CD38 antibody drug conjugate | |
KR20160113623A (en) | Antibody-drug conjugates and immunotoxins | |
JP2020531471A5 (en) | ||
EP4110405A1 (en) | Anti-cd56 antibody-drug conjugates and their use in therapy | |
CN117500527A (en) | Antibody drug conjugate, preparation method and application thereof | |
RU2011127520A (en) | Glucagon-like protein-1 receptor agonists (GLP-1R) | |
CN115052663A (en) | ALK5 inhibitor conjugates and uses thereof | |
JP2024059856A (en) | Antibody-ALK5 inhibitor conjugates and uses thereof | |
RU2009117290A (en) | ANTIANGIOGENIC COMPOUNDS | |
TW202400245A (en) | Antibody-drug conjugates and preparation methods and use thereof | |
RU2022103892A (en) | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 30-2011 FOR TAG: (57) |
|
RH4A | Copy of patent granted that was duplicated for the russian federation |
Effective date: 20130405 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140108 |